
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals Inc. has demonstrated robust patient outcomes with its lead product, etripamil, which has shown significant improvements in symptom relief and treatment satisfaction, highlighted by a p-value of less than 0.0001 in effectiveness measures. The product’s favorable clinical trial results, including statistically significant improvements in global satisfaction (p=0.0069) and effectiveness (p=0.0015), underscore its potential value in managing atrial fibrillation. Despite existing challenges, the company’s prospects remain optimistic, with analysts suggesting that the current issues raised in the Complete Response Letter (CRL) are manageable, indicating a positive trajectory toward eventual regulatory approval.
Bears say
Milestone Pharmaceuticals Inc has faced significant regulatory and clinical setbacks in recent years, which have negatively impacted investor confidence and contributed to a diminished stock performance. The competitive landscape presents further challenges, as emerging market products may disrupt demand for etripamil, potentially leading to reduced future revenue projections. Additionally, the current high standards for funding diligence in the biopharmaceutical sector have made it difficult for the company to attract investment, exacerbating its financial difficulties.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares